دورية أكاديمية
Inhaled molgramostim therapy for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP): a plain language summary of the IMPALA trial.
| العنوان: | Inhaled molgramostim therapy for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP): a plain language summary of the IMPALA trial. |
|---|---|
| المؤلفون: | Trapnell BC; Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. |
| المصدر: | Hospital practice (1995) [Hosp Pract (1995)] 2024 Aug; Vol. 52 (3), pp. 47-63. Date of Electronic Publication: 2024 Aug 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101268948 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2154-8331 (Print) Linking ISSN: 21548331 NLM ISO Abbreviation: Hosp Pract (1995) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon : Taylor & Francis Original Publication: Minneapolis : McGraw-Hill Healthcare Publications, 1995- |
| مواضيع طبية MeSH: | Pulmonary Alveolar Proteinosis*/drug therapy, Humans ; Administration, Inhalation ; Autoimmune Diseases/drug therapy ; Granulocyte-Macrophage Colony-Stimulating Factor/administration & dosage ; Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use |
| فهرسة مساهمة: | Keywords: GM-CSF; Lavage: Luh-vahj; Molgramostim: Mol-gram-oh-stim; Pulmonary alveolar proteinosis: Pull-mon-air-i al-ve-oh-lar pro-teen-oh-sis; Surfactant: Sur-fak-tuhnt; aPAP; autoimmune pulmonary alveolar proteinosis; molgramostim; plain language summary; surfactant; whole-lung lavage Local Abstract: [plain-language-summary] What is this summary about? This is a plain language summary of a late-stage clinical trial called IMPALA, originally reported in The New England Journal of Medicine . The IMPALA trial studied a drug called molgramostim nebulizer solution (molgramostim) to see how well it worked and how safe it was in patients with autoimmune pulmonary alveolar proteinosis (aPAP). Normally, tiny air sacs (alveoli) in the lungs are covered by a thin layer of an oily substance called surfactant that helps to keep them open. In aPAP, surfactant builds up and clogs alveoli making it difficult to breathe. Inhaled molgramostim helps to reduce the amount of surfactant clogging the alveoli.What were the results of the trial? After 24 weeks of treatment, patients who received molgramostim every day had better oxygen transfer into blood than patients who received an inactive substance (placebo). Patients’ sense of well-being and quality of life was improved more with daily molgramostim than placebo. The amount of surfactant in the lungs measured using scans and the number of whole-lung lavages (lung washes) patients required were lower with daily molgramostim than placebo. The number of medical problems (adverse events) was similar in patients who received molgramostim and placebo except for chest pain, which was more common with molgramostim.What do the results of the trial mean? The IMPALA trial demonstrated that molgramostim is a promising treatment option for people with aPAP. |
| المشرفين على المادة: | 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor) |
| SCR Disease Name: | Pulmonary Alveolar Proteinosis, Acquired |
| تواريخ الأحداث: | Date Created: 20240821 Date Completed: 20240904 Latest Revision: 20240904 |
| رمز التحديث: | 20240904 |
| DOI: | 10.1080/21548331.2024.2367955 |
| PMID: | 39165153 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 2154-8331 |
|---|---|
| DOI: | 10.1080/21548331.2024.2367955 |